Viewing Eye Care Network

ASCRS

Shorts

A Pterygium Technique With No Sutures, No Glue
0:38
A Pterygium Technique With No Sutures, No Glue
7 months ago
The Stakes of Ignoring the Ocular Surface
1:01
The Stakes of Ignoring the Ocular Surface
7 months ago
Why Pump Selection Changes Everything: A Physician Perspective
1:00
Why Pump Selection Changes Everything: A Physician Perspective
7 months ago
Safer Phaco: Dual-Pump Fluidics & Endothelial Cell Preservation
0:39
Safer Phaco: Dual-Pump Fluidics & Endothelial Cell Preservation
7 months ago
One Thing Primary Care Should Know About Dry Eye
0:40
One Thing Primary Care Should Know About Dry Eye
7 months ago
The Excitment Around the TECNIS Odyssey and PureSee Lenses
1:20
The Excitment Around the TECNIS Odyssey and PureSee Lenses
7 months ago
ASCRS 2026: Main Themes and Takeaways
0:39
ASCRS 2026: Main Themes and Takeaways
7 months ago
First-Line Treatment: Latanoprostene Bunod or Prostaglandin?
1:44
First-Line Treatment: Latanoprostene Bunod or Prostaglandin?
7 months ago
Going Glasses-Free Post Cataract Surgery: A Physician's First Question
1:25
Going Glasses-Free Post Cataract Surgery: A Physician's First Question
7 months ago
Choosing the Right MIGS Procedure
0:46
Choosing the Right MIGS Procedure
7 months ago

Latest Content

Last year, the company announced the data from the Saturn-1 study for TP-03, the first potential product to treat Demodex blepharitis, and the product is now in the phase 3 trial (Saturn-2). Aziz Mottiwala, chief commercial officer for Tarsus, gives a company update on the pipeline for their program for Demodex blepharitis.

In a presentation at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting, Marjan Farid, MD, ABO, and Preeya K. Gupta, MD, offered details of clinical trials for CSF-1 ophthalmic solution, a presbyopia eye drop candidate. Results showed that nearly half of the participants treated with CSF-1 achieved a 3-line or more increase in the distance-corrected near visual acuity an hour after drop instillation on day 15.

According to an e-poster presented by Jagadesh C. Reddy, MD, and Harini Indusekar, BScOptom, at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., patients who have pre-existing DR are less likely to achieve Snellen 20/40 or better vison after cataract surgery compared with the patients with diabetes but without DR.

Blake K. Williamson, MD, MPH, MS, and coauthor Urvi Patel, BSc, presented an e-poster at the American Society of Cataract and Refractive Surgery’s 2022 annual meeting in Washington, D.C., on the efficacy of a combination eye drop comprised of an antibiotic, anti-inflammatory and lubricant as part of a postoperative treatment regimen following cataract surgery.

For the first time, Orasis Pharmaceutical's phase 2b data for the company's novel candidate for the treatment of presbyopia, CSF-1, a preservative-free solution that contains a proprietary combination of low-dose pilocarpine and multi-faceted vehicle, will be presented during ASCRS by Marjan Farid, MD, and Preeya Gupta, MD. The company recently released its phase 3 topline results. Orasis' Paul Smith, president and COO, talks with Ophthalmology Times' Sheryl Stevenson about this data and the findings' relevance to patients and providers.